Elan shareholders approve $1 billion share buyback
DUBLIN, April 12
DUBLIN, April 12 (Reuters) - Irish drugmaker Elan won approval from shareholders on Friday to commence a $1 billion share buyback as it seeks to keep them on side and stave off an approach from U.S. investment firm Royalty Pharma
The buyback was priced between $11.25 and $13.00 per share and is part of plans to return cash to investors after the $3.2 billion sale of Elan's interest in multiple sclerosis drug Tysabri. It was backed by 99.2 percent of shareholders at a special meeting.
Royalty said it reserved the right to reduce its indicative approach of $11 per share if the buyback went through but it may also sweeten its proposal by paying more if Tysabri, which Elan still receive royalties for, hits certain sales milestones, two people familiar with the matter told Reuters.
- China anxiety knocks shares, oil
- NATO countries have begun arms deliveries to Ukraine: defense minister |
- Alibaba worried about Facebook IPO as considered Nasdaq versus NYSE
- North Korea sentences U.S. citizen Matthew Miller to six years hard labor |
- U.S. sees Middle East help fighting IS, Britain cautious after beheading